文献速递MDS 与骨髓增殖性肿瘤白血病

骨髓增生异常性肿瘤与急性髓系白血病治疗中的克隆演化及凋亡抵抗:整合纵向分析带来的见解

Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.
PubMed 文献 · Leukemia · 2025-09-19

该单中心纵向样本研究对高危骨髓增生异常性肿瘤(hr-MDS)及(继发性)急性髓系白血病(AML)患者进行遗传、蛋白质组及功能性凋亡分析,基线遗传特征分析55例,纵向分析268例(平均8.7个时间点,范围3-20)。发现高BCL-2依赖性与阿扎胞苷联合维奈克拉(aza/ven)的遗传学缓解及总生存改善相关,而BCL-xL依赖增加与耐药相关。

要点

  • 基线遗传特征分析55例,纵向分析268例(平均8.7个时间点,范围3-20)。
  • 高BCL-2依赖性与aza/ven遗传学缓解及总生存改善相关。
  • BCL-xL依赖增加与耐药相关,体外抑制BCL-xL可有效逆转BCL-xL依赖增加病例的耐药。

核心结论

  • 该研究刻画了MDS和AML治疗相关的克隆演化,为临床反应、疾病进展及潜在个体化治疗策略提供了见解。

研究设计与样本

  • 单中心纵向样本收集,对MDS和AML/sAML患者进行全面的遗传、蛋白质组和功能性凋亡谱分析。
  • 基线遗传特征分析n=55,纵向分析n=268(平均8.7个时间点,范围3-20)。

主要发现

  • 基线遗传特征分析(n=55)识别出高危遗传学改变,纵向分析(n=268,平均8.7个时间点,范围3-20)揭示克隆演化的不同遗传学特征。
  • 治疗开始时功能性BH3谱分析识别出对BCL-2家族成员依赖的异质性。
  • 高BCL-2依赖性与aza/ven的遗传学缓解及总生存改善相关,而BCL-xL依赖增加与耐药相关。
  • 识别出获得性耐药模式,凋亡启动丧失及抗凋亡依赖性转变导致治疗失败。
  • BH3谱分析在个别病例中揭示向MCL-1和/或BCL-xL的功能性转变,提示潜在治疗靶点以克服耐药;体外BCL-xL抑制有效对抗BCL-xL依赖增加病例的耐药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of high-risk Myelodysplastic Neoplasms (hr-MDS) and (secondary) Acute Myeloid Leukemia (AML) remains a clinical challenge. The combination of azacitidine and venetoclax (aza/ven) may improve treatment outcomes, but still fails in a significant fraction of patients. We established a single-center collection of longitudinal samples from patients with MDS and AML/sAML and performed comprehensive genetic, proteomic and functional apoptosis profiling to identify biomarkers and targetable escape mechanisms to aza/ven. Baseline genetic characterization (n = 55) identified high-risk genetic alterations, while longitudinal analyses (n = 268, mean 8.7 [3-20] timepoints) revealed distinct genetic profiles of clonal evolution. Functional BH3-profiling at treatment initiation identified heterogeneous dependencies on BCL-2 family members. Notably, high BCL-2 dependence correlated with genetic response to aza/ven and improved overall survival, whereas increased BCL-xL dependence was associated with resistance. We further identified patterns of acquired resistance, with loss of apoptotic priming and shifts in anti-apoptotic dependencies contributing to treatment failure. BH3 profiling revealed functional shifts toward MCL-1 and/or BCL-xL in individual cases, suggesting potential therapeutic targets to overcome resistance. In vitro, BCL-xL inhibition effectively counteracted resistance in increased BCL-xL dependence cases. In summary, we characterized treatment-associated clonal evolution in MDS and AML, providing insights into clinical response, disease progression and potential individualized therapeutic strategies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mazzeo P, Penir SM, Shumilov E, et al. Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling. Leukemia. 2025. PMID: 40973765. doi:10.1038/s41375-025-02756-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。